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Abstract
Background: Electrocardiogram (ECG) cardiovascular disease (CVD) abnormalities (ECG-CVD) are predictive of
subsequent CVD events in the general population. Systemic lupus erythematosus (SLE) patients are vulnerable to
CVD. We aimed to determine the prevalence of ECG-CVD in SLE patients and to examine the risk factors associated
with ECG-CVD.
Methods: A 12-lead resting supine ECG was performed on consecutive adult patients attending the clinic. One
cardiologist interpreted the ECGs. ECG-CVD were defined as the presence of one or more of the following 4
elements (ECG-4): ST-segment and/or T-wave abnormalities, left ventricular hypertrophy (LVH), left axis deviation
(LAD), left bundle branch block (LBBB) and right bundle branch block (RBBB). ECG-5 included the same elements as
ECG-4 and the Q-wave. Repeated measurement data were created and the associations between ECG-4/ECG-5 and
demographics were evaluated with univariate and multivariate Cox regression models.
Results: Of 487 SLE patients, 104 (21.4%) and 118 (24.2%) patients had one or more of the ECG-4 and ECG-5
elements, respectively. A higher prevalence of ECG-CVD was found in patients with a longer SLE disease duration,
and the burden of ECG-CVD elements increased with age. Increased age, active SLE disease, and damage were
associated with ECG4 and ECG-5, while treatment of hyperlipidemia was protective.
Conclusion: A high prevalence of ECG-4 (21.4%) and ECG-5 (24.2%) was found in this SLE cohort. Controlling SLE
disease activity is important since it was associated with ECG-4 and ECG-5. Early identification of ECG-4 and ECG-5
in SLE patients might allow for better stratification and risk management.
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Background
Substantial progress has been made in the awareness
and prevention of coronary artery disease (CAD) in pa-
tients with systemic lupus erythematosus (SLE) since the
first published reports in long-term observational cohort
studies of clinical CAD in an estimated 6–10% of SLE
patients [1, 2]. The prevalence of myocardial infarction
(MI)/angina and sudden death in the Toronto SLE clinic
was approximately 10% in 1995 [3], and a similar preva-
lence of CAD has been reported in other SLE cohorts
[4, 5]. SLE is now recognized as an independent risk fac-
tor for cardiovascular disease (CVD) [6] and, as such,
was incorporated into the recently revised American
Heart Association guidelines for the prevention of CVD
in women [7]. Abnormalities detected on resting electro-
cardiogram (ECG) in healthy adults are associated with
an increased risk for subsequent CVD events [8]. In a
systematic review, Chou et al. [8] found that resting
ECG abnormalities (ECG-CVD 4-elements), in particular
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ST-segment and/or T-wave abnormalities, left ventricu-
lar hypertrophy (LVH), left axis deviation (LAD), left
bundle branch block (LBBB) and right bundle branch
block (RBBB), were associated with subsequent CVD
events (e.g., sudden coronary heart disease death, nonfa-
tal myocardial infarction, and congestive heart failure).
In their systematic review, Chou et al. reported other
resting ECG abnormalities (e.g., prolonged QT interval,
Q waves, arrhythmia, and others) but these ECG find-
ings were evaluated by too few studies or were too vari-
ably defined to have clear conclusions about their
usefulness as predictors of subsequent CVD events [8].
The objective of this study was to determine the preva-
lence of ECG-CVD (4-elements (ECG-4) as per Chou
et al., and 5-elements (ECG-5) as per Chou et al. or Q
wave) in a cohort of SLE patients, and to examine the
factors associated with ECG-4 and ECG-5.
Methods
Setting
A standard digitally recorded 12-lead resting supine
ECG was performed on consecutive adult SLE patients
≥18 years, with 4 or more of the American College of
Rheumatology (ACR) criteria or 3 ACR criteria plus a
typical histological lesion of SLE on renal or skin biopsy
[9] attending the University of Toronto SLE Clinic from
October 2011 to November 2015. All patients were eval-
uated according to the standard clinic protocol which in-
cludes demographics, assessment of disease activity (SLE
Disease Activity Index 2000 (SLEDAI-2 K)) [10] and
damage (SLICC/American College of Rheumatology
Damage Index (SDI)) [11], current and past glucocortic-
oid, antimalarial, antihypertensive, and immunosuppres-
sant medication use, and laboratory tests at each visit.
Patients were followed prospectively every 2 to 6 months.
The following data were collected on all patients as part
of the regular databank protocol and were made avail-
able for this study. Patients were considered to have a
positive smoking status if they were documented as a
current smoker at any point in the 5 years preceding the
date of ECG. History of cardiovascular events (MI, an-
gina, angioplasty, congestive heart failure and pace-
maker), diabetes mellitus (DM) 3 years before ECG,
hyperlipidemia on statins ever prior to ECG, and hyper-
tension within 5 years from ECG (>140 mmHg systolic
or >90 diastolic mmHg, or using medication for hyper-
tension) were extracted. Patients were considered posi-
tive for antiphospholipid antibodies (aPLA) if they had
ever been positive for aPLA, including total anticardioli-
pin antibodies and individual anticardiolipin antibodies
(aCL IgG/aCL IgM) (Phadia Varelisa kits, Somagen for
anticardiolipin antibodies screen and IgG and IgM as-
says) measured yearly by enzyme-linked immunosorbent
assay (ELISA) [12]. The clotting assays for SLE
anticoagulant included the dilute Russell viper venom
time and the platelet neutralization procedure. SLE anti-
coagulant (LA) was considered present if patients tested
positive on two or more occasions since joining the SLE
cohort. Other laboratory variables were evaluated: ANA,
anti-ds DNA, anti-Ro, anti-La, anti-Smith, anti-RNP,
anti-Jo1 antibodies, ANCA, and Coombs tests (ever-
positive 5 years prior to ECG).
The ECGs had all identifying data removed and so
were read “blind”. The coded 12-lead ECGs were evalu-
ated and interpreted by one senior cardiologist (PH)
using the Minnesota code classification system, which
is a widely used method of categorizing ECG abnormal-
ities [13].
All patients provided informed consent for the collec-
tion, storage, and use of clinical and laboratory data fol-
lowing procedures in accordance with the Declaration of
Helsinki and approved by the University Health Network
Research Ethics Board, Toronto, Ontario, Canada.
Patient selection
Consecutive SLE patients seen at the SLE clinic from
October 2011 to November 2015 were recruited to this
study. Patients were excluded if they had had a CVD
event (MI, angina, congestive heart failure (CHF), angio-
plasty and pacemaker) prior to ECG.
Study design
SLE patients were grouped into those with normal ECG
and those with ECG-CVD. ECG-CVD patients were fur-
ther grouped into two: ECG-4 (with one or more of the
following abnormalities—LBBB/RBBB, LAD/left anterior
fascicular block (LAFB), LVH, and ST-segment and/or
T-wave abnormalities); and ECG-5 (any of the above or
pathological Q wave) (Fig. 1). Our study focuses on pa-
tients with ECG-4 and ECG-5 compared to patients with
a normal ECG. Descriptive analyses of patient demo-
graphics, disease activity, damage, and antibody abnor-
malities were studied in the following groups: patients
with normal ECG, patients with ECG-4, and patients
with ECG-5. The clinical/laboratory data available at the
time of ECG were used to study the association with
ECG-CVD. The adjusted mean SLEDAI-2 K (AMS) was
calculated using SLEDAI-2 K 2 years prior to the ECG
visit [14].
Statistical analyses
Simple statistics at baseline (at the first visit to the clinic)
were described by mean and percentages for continuous
and categorical variables. The differences between the
group of patients with normal ECG and the group of pa-
tients with ECG-CVD (ECG-4 and ECG-5) were com-
pared by t test and chi-square test.
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A counting process data structure was created for the
outcome of both ECG-4 and ECG-5. Patient sex, ethni-
city, time from first visit to the clinic to the time of
ECG, hypertension, hyperlipidemia on statin therapy, la-
boratory test (antibodies), smoking ever before ECG, dis-
ease activity, and diabetes 3 years before ECG test were
extracted as time-fixed variables. Other variables such as
organ damage and treatment were extracted as time-
variant variables.
Univariate Cox regression was performed to test each
risk factor, comparing normal ECG and ECG-4 and
ECG-5. The variables with p value less than 0.2 were en-
tered into the multivariate regression. The traditional
risk factors for CAD including hypertension and smok-
ing were forced into the model.
Cox regression proportionalities were checked by the
Schoenfeld residuals, and continuous variables were tested
for their linearity using Martingale residuals. The time-
dependent multivariate Cox regression model was built
using a step-down covariate-selection approach; Akaike
information criterion (AIC) adjusting the number of co-
variates in the model was adopted as the method assessing
the goodness of fit. Both hypertension and smoking were
forcedly added to the multivariable regression but did not
show an association with ECG-4 and ECG-5. The analysis




Among the 558 adult SLE patients who had an ECG,
44% were inception (patients who joined the SLE clinic
within 1 year from the diagnosis of SLE). Seventy-one
patients were excluded as they had CAD before the
ECG test. A total of 487 ECGs were evaluated of which
314 patients (64.4%) had a normal ECG. The prevalence
of ECG-4 was 21.4% (104/487 patients) and the preva-
lence of ECG-5 was 24.2% (118/487 patients). The most
common element of ECG-4 was ST-segment abnormal-
ities and/or T-wave abnormalities (73/104; 70%),
followed by LVH in 32%, LAD or LAFB in 20%, and
LBBB or RBBB in 11%. In ECG-5, Q-wave was found in
18% (21/118) of the patients. The ECG-CVD elements
were found as one ECG-CVD element in 67% (70/104)
in the ECG-4, two ECG-CVD elements in 25% (26/
104), and 7% (7/104) had three ECG-CVD elements.
ECG-CVD was seen more often with longer disease
duration (Fig. 2). Other ECG abnormalities documented
in 55 patients were: right axis deviation in 9 patients,
incomplete RBBB in 3 patients, atrial enlargement in 7
patients, and arrhythmia in 36 patients (sinus tachycardia
in 9 patients, sinus bradycardia in 11, short PR in 8, first
A-V block in 3, ectopic atrial rhythm in 3, premature atrial
contraction in 3, and ventricular bigeminy in 1 (few
patients had overlaping types of arrhythmia).
Fig. 1 Study design and grouping of patients: normal electrocardiogram (ECG), non-ECG-cardiovascular disease (ECG-CVD), ECG-4, and ECG-5.
Non-ECG-CVD defined as the presence of any of the following ECG abnormalities: right axis deviation, arrhythmia, sinus tachycardia, sinus
bradycardia, atrioventricular blocks, atrial ectopic rhythm, and atrial enlargement
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Patient characteristics
The baseline (at first visit to the clinic) characteristics of
the patients were similar in SLE patients with a normal
ECG and those with ECG-CVD (Table 1). A higher
prevalence of ECG-4 and ECG-5 was identified among
older SLE patients. Patients with longer SLE disease dur-
ation had more prevalence of ECG-4 and ECG-5 com-
pared to patients with a normal ECG (19.48 ± 11.03 vs.
15.23 ± 10.16, p < 0.001). Patient with longer lupus
follow-up duration (13.69 ± 11.29 years) at the time of
Fig. 2 Cumulative proportions of individual ECG-5 from systemic lupus erythematosus (SLE) diagnosis up to 20 years of follow-up (e.g., 11 out of
21 (52.4%) patients had LAD/LAFB up to 20 years and the other 10 LAD/LAFB occurred after 20 years of follow-up). ECG-CVD electrocardiogram
cardiovascular disease abnormalities, LAD left axis deviation, LAFB left anterior fascicular block, LBBB left bundle branch block, LVH left ventricular
hypertrophy, RBBB right bundle branch block









Female 286 (91.1%) 92(88.5) 0.43 104 (88.1%) 0.357
Male 28 (8.9%) 12 (11.5%) 14 (11.9%)
Ethnicity
Caucasian 181 (58.2%) 59 (57.8%) 0.09 69 (59.5%) 0.146
Black 51 (16.4%) 26 (25.5%) 27 (23.3%)
Asian 38 (12.2%) 10 (9.8%) 12 (10.3%)
Others 41 (13.2%) 7 (6.4) 8 (6.9%)
Age at SLE diagnosis (years) 29.6 ± 11.3 30.66 ± 11.01 0.42 30.46 ± 11.86 0.50
Age at ECG (years) 44.87 ± 12.9 50.14 ± 14.1 <0.001 49.95 ± 15.01 <0.001
Disease duration at ECG (years) 15.23 ± 10.2 19.48 ± 11.03 <0.001 19.49 ± 11.44 <0.001
Follow-up duration at ECG (years) 10.57 ± 9.4 13.69 ± 11.29 0.006 13.41 ± 11.24 0.008
SLEDAI-2 K at the first visit 9.24 ± 8.3 10.2 ± 7.78 0.30 9.82 ± 7.67 0.52
SDI 0.27 ± 0.7 0.44 ± 0.92 0.07 0.44 ± 0.90 0.06
Cumulative glucocorticoid (g) 5.24 ± 16.5 9.16 ± 31.25 0.10 8.96 ± 29.85 0.10
Treated with antimalarials 147 (46.8%) 51 (49.0%) 0.69 59 (50.0%) 0.55
Treated with immunosuppressives 93 (29.6%) 33 (31.7%) 0.68 37 (31.4%) 0.73
Hypertension 153 (48.7%) 65 (62.5%) 0.015 74 (63.6%) 0.006
Hyperlipidemia on statins ever before ECG 87 (27.7%) 40 (38.5%) 0.039 44(37.3%) 0.05
DM 3 years prior to ECG 16 (5.1%) 4 (3.8%) 0.60 4 (3.4%) 0.45
Smoking ever prior to ECG 91 (29%) 30 (28.8%) 0.97 34 (28.8%) 0.91
Values are shown as mean ± SD or n (%) as appropriate
p values are from t test for means, Chi-Square test for binary variables, and Cochran-Armitage trend test for categorical variables
DM diabetes mellitus, ECG electrocardiogram, SDI SLICC/American College of Rheumatology Damage Index, SLE systemic lupus erythematosus, SLEDAI-2 K SLE
Disease Activity Index 2000
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ECG had a higher prevalence of ECG-4 (p = 0.006) ver-
sus a normal ECG with a follow-up duration at the time
of the ECG of 10.57 ± 9.40 years. Also, patients with lon-
ger lupus follow-up duration at the time of ECG have a
higher prevalence of ECG-5. Hypertension within 5 years
prior to the ECG was associated with a high prevalence
of ECG-4 and ECG-5 (p = 0.015 and p = 0.006, respect-
ively). There were no significant differences between a
normal ECG and ECG-4 or ECG-5 among the other var-
iables (SDI, SLEDAI-2 K, smoking, DM, and treatment
with antimalarials or immunosuppressives) (Table 1).
There was no difference in the antibodies profile be-
tween normal ECG and ECG-4 and ECG-5 (data not
shown).
Univariate analysis
Both ECG-4 and ECG-5 were significantly associated
with non-Caucasian ethnicity, longer lupus disease dur-
ation, and with increasing age of the SLE patients at
each visit. Patients with ECG-4 and ECG-5 had more ac-
tive SLE disease activity (AMS 2 years prior to ECG
visit) and more damage (SDI) compared to patients with
normal ECG. Treatment, including glucocorticoids, anti-
malarials, and immunosuppressives, was associated with
ECG-4 and ECG-5. Other classic CVD risk factors such
as smoking and hypertension were not associated with
ECG-4 or ECG-5 in the univariate analysis (Table 2).
Multivariate analysis
ECG-4
The multivariate Cox regression showed that older age,
SLE disease activity (AMS 2 years prior to ECG), and
SDI are associated with ECG-4. Older patients were
more likely to have ECG-4, with a 4% increase in hazard
ratio (HR) for every 1-year increase in age (HR = 1.05;
95% confidence interval (CI): 1.01–1.07; p = 0.002). Pa-
tients with active SLE (AMS 2 years prior to ECG visit)
and patients with more damage (SDI) were more likely
Table 2 Univariate Cox regression analysis for ECG-4 and ECG-5
ECG-4 ECG-5
Variables HR (95% CI) p HR (95% CI) p
Non-Caucasian 1.91 (1.27–2.86) 0.002 1.63 (1.11–2.37) 0.012
Gender (male) 1.13 (0.62–2.07) 0.68 1.19 (0.68–2.09) 0.53
Age 1.03 (1.007–1.05) 0.01 1.02 (1.004–1.05) 0.02
Disease duration 1.06 (1.03–1.09) 0.0007 1.05 (1.014–1.09) 0.006
Hypertension within 5 years prior to ECG 0.88 (0.49–1.57) 0.67 0.91 (0.52–1.58) 0.73
Hyperlipidemia on statins ever before ECG 0.59 (0.30–1.13) 0.11 0.54 (0.29–1.01) 0.05
Ever smoked before ECG 0.72 (0.39–1.35) 0.31 0.75 (0.42–1.35) 0.34
Diabetes 3 years before ECG 0.75 (0.27–2.04) 0.09 0.75 (0.27–2.048) 0.57
SLEDAI-2 K 1.05 (1.012–1.013) 0.01 1.05 (1.01–1.09) 0.008
AMS 2 years prior to ECG 1.08 (1.02–1.13) 0.005 1.08 (1.03–1.13) 0.003
SDI 1.23 (1.07–1.41) 0.003 1.21 (1.06–1.39) 0.006
Cumulative glucocorticoids 1.007 (1.001–1.01) 0.02 1.007 (1.001.013) 0.02
Treated with antimalarials 2.27 (1.12–4.59) 0.02 2.11 (1.11–4.04) 0.02
Treated with immunosuppressives 2.15 (1.21–3.83) 0.009 2.06 (1.19–3.55) 0.009
Coombs 1.19 (0.81–1.76) 0.37 1.19 (0.83–1.73) 0.33
Anti-Jo1 0.65 (0.26–1.63) 0.36 0.71 (0.30–1.64) 0.41
Anti-La 0.79 (0.47–1.34) 0.39 0.8 (0.49–1.31) 0.38
Anti-RNP 1.18 (0.791.74) 0.41 1.24 (0.86–1.79) 0.24
Anti-Ro 0.81 (0.56–1.18) 0.27 0.79 (0.55–1.14) 0.21
Anti-Scl70 0.49 (0.15–1.59) 0.24 0.45 (0.14–1.44) 0.19
Anti-Smith 1.43 (0.89–2.27) 0.13 1.44 (0.93–2.22) 0.11
ANCA 0.63 (0.32–1.21) 0.17 0.63 (0.34–1.18) 0.15
Anti-ds DNA 1.52 (1.02–2.29) 0.041 1.48 (1.01–2.16) 0.04
ANA 0.86 (0.38–1.97) 0.72 0.74 (0.36–1.53) 0.42
APLA 0.85 (0.53–1.35) 0.48 0.73 (0.49–1.23) 0.29
AMS adjusted mean SLEDAI-2 K, CI confidence interval, ECG electrocardiogram, HR hazard ratio, SDI SLICC/American College of Rheumatology Damage Index, SLE
systemic lupus erythematosus, SLEDAI-2 K SLE Disease Activity Index 2000
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to have ECG-4 (HR = 1.08; 95% CI: 1.02–1.16; p = 0.009
and HR = 1.29; 95% CI: 1.1–1.53; p = 0.002, respectively).
Statin treatment for hyperlipidemia was protective
against ECG-4 (HR = 0.43; 95% CI: 0.21–0.89; p = 0.02).
There was a trend for immunosuppressive therapy to be
associated with ECG-4 (p = 0.05). This trend of associ-
ation can be explained by the use of immunosuppressive
therapy in the context of active lupus disease, especially
that ECG-4 was also associated with AMS.
ECG-5
The results of the multivariate analysis for ECG-5 were
similar to ECG-4, and showed an association with older
age (HR = 1.04; 95% CI: 1.007–1.06; p = 0.01), SLE dis-
ease activity (AMS 2 years prior to ECG; HR = 1.07 95%
CI: 1.002–1.14; p = 0.04), and SDI (HR = 1.28; 95% CI:
1.08–1.51; p = 0.004) (Table 3).
Discussion
It is well established that SLE patients have increased
mortality secondary to cardiovascular events even in the
absence of traditional risk factors for CVD [15]. In this
study of SLE patients, the prevalence of the ECG-4,
which have been shown by Chou et al. to be predictive
of CVD [14], is 21.4% and the prevalence of ECG-5 is
24.2%. The prevalence of ECG-CVD among SLE patients
is greater than the general population (prevalence 3.6–
17%) as shown in Table 4. Chou et al. showed that ECG-4
predicts subsequent CVD events [16] and that patho-
logical Q-wave was also a predictor of future CVD [14]. In
this study, ECG-CVD (ECG-4 and ECG-5) was more
common in patients aged 50.14 ± 14.1 years compared to
the group without ECG-CVD (age 44.8 ± 12.9 years); how-
ever, this is still younger than the general population.
In our analysis, we found an association between
ECG-CVD (ECG-4 and ECG-5) and lupus disease activ-
ity (AMS 2 years prior to ECG) and damage (SDI). Some
studies have found an association of azathioprine with
atherosclerosis [17, 18]. Although there was a trend in
our study for an association with immunosuppressive
drugs (azathioprine, mycophenolate mofetil, cyclophos-
phamide, cyclosporine, and methotrexate), this was not
statistically significant. Cumulative glucocorticoid ther-
apy has been postulated as a potential risk factor for ath-
erosclerosis in patients with SLE [2, 19, 20], but not all
studies have confirmed this association [21]. In this
study, cumulative glucocorticoid therapy and antimalar-
ial drugs were significantly associated with ECG-4 and
ECG-5 in the univariate analysis, but did not remain in
the multivariate analysis. Statin therapy ever for hyper-
lipidemia was protective against ECG-CVD in the multi-
variate analysis.
While some previous studies showed an association be-
tween antiphospholipid antibodies and clinical CVD and/
or events [20, 22], other studies did not [17, 21, 23]. In the
present study, antiphospholipid antibodies were not asso-
ciated with ECG-4 or ECG-5. More recently, Andrade
et al. showed that patients with antiphospholipid syn-
drome do not develop premature atherosclerosis [24].
Smoking, hypertension, and DM, all recognized as trad-
itional risk factors for CVD in SLE patients [2, 23], were
not significantly associated with ECG-CVD this study.
Several factors could explain the lack of association with
traditional risk factors for CVD in our study. First, smok-
ing ever was reported in 29% of each of the non-CVD and
ECG-4 and -5 groups, and other studies have demon-
strated the importance of studying the dose-effect (pack-
years) of smoking [25]. Second, in CAD, the ECG is the
reflection of damage to the myocardium that usually oc-
curs at the end of the process of the development of CAD
and its clinical implications. Third, with respect to hyper-
tension, not only is LVH a reflection of long-term inad-
equate control of blood pressure, but ECG has a poor
sensitivity for LVH (slightly lower in females than in
males). Fourth, the number of patients with DM was small
(only four patients had DM in ECG-4 and -5).
Table 3 Multivariate Cox regression analysis for ECG-4 and ECG-5
ECG-4 ECG-5
Variables HR (95% CI) p HR (95% CI) p
Age at each visit 1.05 (1.01–1.07) 0.002 1.04 (1.007–1.06) 0.01
AMS (2 years prior to ECG) 1.08 (1.02–1.16) 0.009 1.07 (1.002–1.14) 0.04
SDI 1.29 (1.10–1.53) 0.002 1.28 (1.08–1.51) 0.004
Hyperlipidemia on statins ever before ECG 0.44 (0.21–0.89) 0.02 0.44 (0.22–0.87) 0.02
Hypertension 0.66 (0.34–1.26) 0.21 0.75 (0.4–1.39) 0.36
Ever smoked before ECG 1.13 (0.59–2.16) 0.71 1.09 (0.58–2.06) 0.77
Immunosuppressive treatment at each visit 1.88 (1.01–3.51) 0.05 1.67 (0.93–3.04) 0.09
Antimalarial treatment at each visit 1.76 (0.87–3.58) 0.12 1.81 (0.92–3.56) 0.12
Akaike information criterion (AIC) = 334.6
AMS adjusted mean SLEDAI-2 K, CI confidence interval, ECG electrocardiogram, HR hazard ratio, SDI SLICC/American College of Rheumatology Damage Index, SLE
systemic lupus erythematosus, SLEDAI-2 K SLE Disease Activity Index 2000
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In the current study, the most common element of
ECG-4 was ST-segment abnormalities and/or T-wave
abnormalities (70%), followed by LVH in 32%, LAD or
LAFB in 20%, and LBBB or RBBB in 11%. In ECG-5, Q-
wave was found in 18% of the patients. The pooled ad-
justed HR (for CVD) of ST-segment abnormalities in
resting ECG in the normal healthy population from sev-
eral studies was found to be 1.9 [26–30]. De Bacquer
et al. showed that ST‐depression is predictive of CVD
[31]. In a recent systematic review, both LVH LAD on
resting ECG were associated with a similar increased
risk for subsequent CVD events, with a pooled adjusted
HR of 1.6 (95% CI, 1.4 to 1.8) [8, 16, 29–32]. LBBB was
found in 3% of ECG-CVD, and it has been previously re-
ported that, in the presence of LBBB on resting ECG,
there is an increased incidence of ischemic heart disease
events and/or death due to cardiovascular disease com-
pared to control subjects [8, 33]. Interestingly, pathological
Q-waves were noted in 11% of the patients with ECG-5
without a previous history of ischemic heart disease.
A limitation of this study is the lack of a control group
to better evaluate the prevalence of CVD-ECG-4 abnor-
malities in patients without SLE. In order to evaluate the
prevalence of CVD-ECG-4 abnormalities, a baseline
ECG should have been done and this is also a limitation
of this study. In addition, the low level of correlation
among variables in the multivariate analyses is a limita-
tion of this study; although we avoided using variables
with moderate to high correlation in the multivariate
analyses, some variables were inter-related to each other
at a low level, e.g., older age and hyperlipidemia (correl-
ation coefficient = 0.30), and age and dsDNA antibodies
(correlation coefficient = –0.22).
Conclusions
SLE is an independent risk factor for cardiovascular dis-
ease [17] and therefore early identification of those SLE
patients at increased risk for premature cardiovascular
disease is crucial to the development and implementa-
tion of effective prevention strategies in this population.
The high prevalence of ECG-4 and ECG-5 in this study
of SLE patients without documented cardiovascular disease
suggests that baseline (and possibly follow-up sequential)
ECG may be a useful non-invasive SLE screening tool for
evaluation and identification of SLE patients at increased
risk for cardiovascular events with relatively minimal cost
burden. Prospective follow-up studies of SLE patients with
ECG-4 and ECG-5 will be helpful to determine the validity
of implementation of targeted cardiovascular prevention
strategies in patients with ECG-CVD.
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• Complete or second AV block
11.1% (female 12.5%,
male 9.6%)
Charleston Heart Study Sutherland et al., 1993 [35] 933 48 (35–74) • ST-segment depression
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De Becquer et al., 1998 [27] 9954 48 (25–74) • ST-segment depression
• T-wave inversion
• LBBB or RBBB
• Atrial fibrillation or flutter
3.6%
Copenhagen ECG Study Rasmussen et al., 2014 [36] 285,194 65 • ST-segment depression Female 7%
Male 8%
The definition of ECG-CVD varied among the included studies in Table 4
ECG-CVD electrocardiogram cardiovascular disease abnormalities, LAD left axis deviation, LBBB left bundle branch block, LVH left ventricular hypertrophy, RBBB
right bundle branch block
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